Abstract 196TiP
Background
Concurrent chemoradiotherapy (cCRT) is the standard therapy for locally advanced gastric and GEJ adenocarcinoma with poor prognosis. Programmed cell death receptor-1 (PD-1) inhibitor has been approved to treat ≥3 line gastric and GEJ patients (pts). PACIFIC study demonstrated significant clinical benefits of PD-1 inhibitor in addition to cCRT in locally advanced lung cancer. Sintilimab, a humanized IgG4 monoclonal antibody with high affinity and specificity for PD-1, has shown promising efficacy with an overall response rate of 85% in combination with chemotherapy in gastric cancer in a phase Ib study (NCT02937116). A study was therefore designed to explore the efficacy and safety of perioperative cCRT in combination with sintilimab for pts with locally advanced gastric cancer.
Trial design
This is a prospective, open label, multicentric phase II trial which pts with locally advanced (cT3N2-3 or cT4aN+ or cT4bNany) gastric or GEJ adenocarcinoma will receive preoperative 4 cycles sintilimab in combination with S1, nab-paclitaxel (nab-PTX) and radiotherapy (RT) and post-operative 3 cycles sintilimab with S1 and nab-PTX. Sintilimab will be administered intravenously at flat dose of 200 mg every 3 wks. S1 orally at dose of 40 mg/m2 (bid) and nab-PTX intravenously at 100-120 mg/m2 (d1, d8) will be given for 2 cycles before surgery and 3 cycles after. A weekly nab-PTX (80-100 mg/m2,d1, d8, d15, d22) with concurrent RT (45Gy/1.8Gy*25f) will be given in between 2 cycles of S1 and nab-PTX combination. The primary endpoint is the pathological complete response (pCR), and a Simon optimal two-stage design will be employed to achieve the target at 35% from historical 15%. Secondary endpoints include safety, major pathological response (MPR) (defined by tumor residual ≤10%), R0 resection rate, and overall survival. Collateral translational studies explore the correlation of response with tumor mutational burden or genetic alterations, or biomarkers etc. The trial is now open to enrollment, 13 of planned 34 pts have been enrolled.
Clinical trial identification
ChiCTR1900024428.
Legal entity responsible for the study
Affiliated Drum Tower Hospital to Medical School of Nanjing University.
Funding
Innovent Biologics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session